Jubilant Pharmova [JUBLPHARMA] vs Concord Biotech [CONCORDBIO] Detailed Stock Comparison

Jubilant Pharmova Ltd.

NSE
Loading...

Concord Biotech Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Jubilant Pharmova Ltd. wins in 11 metrics, Concord Biotech Ltd. wins in 9 metrics, with 0 ties. Jubilant Pharmova Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Jubilant Pharmova Ltd. Concord Biotech Ltd. Better
P/E Ratio (TTM) 33.71 34.14 Jubilant Pharmova Ltd.
Price-to-Book Ratio 2.21 5.86 Jubilant Pharmova Ltd.
Debt-to-Equity Ratio 43.87 0.09 Concord Biotech Ltd.
PEG Ratio -0.74 -2.10 Jubilant Pharmova Ltd.
EV/EBITDA 13.71 24.23 Jubilant Pharmova Ltd.
Profit Margin (TTM) 5.46% 26.97% Concord Biotech Ltd.
Operating Margin (TTM) 7.95% 28.89% Concord Biotech Ltd.
EBITDA Margin (TTM) 7.95% 28.89% Concord Biotech Ltd.
Return on Equity 13.45% 20.50% Concord Biotech Ltd.
Return on Assets (TTM) 6.58% 18.27% Concord Biotech Ltd.
Free Cash Flow (TTM) $-435.00M $1.33B Concord Biotech Ltd.
Dividend Yield 0.85% 0.44% Jubilant Pharmova Ltd.
1-Year Return -14.60% -37.20% Jubilant Pharmova Ltd.
Price-to-Sales Ratio (TTM) 1.83 9.18 Jubilant Pharmova Ltd.
Enterprise Value $166.18B $104.46B Jubilant Pharmova Ltd.
EV/Revenue Ratio 2.31 9.02 Jubilant Pharmova Ltd.
Gross Profit Margin (TTM) 66.15% 76.33% Concord Biotech Ltd.
Revenue per Share (TTM) $500 $110 Jubilant Pharmova Ltd.
Earnings per Share (Diluted) $27.21 $29.77 Concord Biotech Ltd.
Beta (Stock Volatility) 0.48 0.58 Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. vs Concord Biotech Ltd. Stock Performance Analysis

Loading Price Chart...

JUBLPHARMA
CONCORDBIO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Jubilant Pharmova Ltd.-0.77%-1.47%-3.33%18.72%-9.08%-8.85%
Concord Biotech Ltd.4.60%10.75%11.00%11.15%-3.65%-0.42%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Jubilant Pharmova Ltd.-14.60%170.97%26.07%257.85%685.10%572.89%
Concord Biotech Ltd.-37.20%28.33%28.33%28.33%28.33%28.33%

Performance & Financial Health Analysis: Jubilant Pharmova Ltd. vs Concord Biotech Ltd.

MetricJUBLPHARMACONCORDBIO
Market Information
Market Cap i₹149.73B₹106.31B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i112,714361,672
90 Day Avg. Volume i181,191257,270
Last Close₹964.45₹1,330.70
52 Week Range₹786.05 - ₹1,248.00₹987.00 - ₹2,150.40
% from 52W High-22.72%-38.12%
All-Time High₹1,309.90 (Nov 04, 2024)₹2,664.00 (Sep 16, 2024)
% from All-Time High-26.37%-50.05%
Growth Metrics
Quarterly Revenue Growth0.17%0.14%
Quarterly Earnings Growth-0.45%-0.15%
Financial Health
Profit Margin (TTM) i0.05%0.27%
Operating Margin (TTM) i0.08%0.29%
Return on Equity (TTM) i0.13%0.21%
Debt to Equity (MRQ) i43.870.09
Cash & Liquidity
Book Value per Share (MRQ)₹415.87₹173.32
Cash per Share (MRQ)₹39.24₹31.25
Operating Cash Flow (TTM) i₹8.86B₹2.98B
Levered Free Cash Flow (TTM) i₹8.39B₹3.72B
Dividends
Last 12-Month Dividend Yield i0.85%0.44%
Last 12-Month Dividend i₹10.00₹8.75

Valuation & Enterprise Metrics Analysis: Jubilant Pharmova Ltd. vs Concord Biotech Ltd.

MetricJUBLPHARMA (Apr 24, 2026)CONCORDBIO (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i33.7134.14
Forward P/E i25.2726.89
PEG Ratio i-0.74-2.10
Price to Sales (TTM) i1.839.18
Price to Book (MRQ) i2.215.86
Market Capitalization
Market Capitalization i₹149.73B₹106.31B
Enterprise Value i₹166.18B₹104.46B
Enterprise Value Metrics
Enterprise to Revenue i2.319.02
Enterprise to EBITDA i13.7124.23
Risk & Other Metrics
Beta i0.480.58
Book Value per Share (MRQ) i₹415.87₹173.32

Financial Statements Comparison: Jubilant Pharmova Ltd. vs Concord Biotech Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricJUBLPHARMA (2025)CONCORDBIO (2025)
Revenue/Sales i71.92B11.80B
Cost of Goods Sold i26.12B3.18B
COGS % of Revenue i36.3%26.9%
Gross Profit i45.81B8.62B
Gross Margin i63.7%73.1%
Research & Development iN/AN/A
Operating Income (EBIT) i8.07B4.63B
Operating Margin i11.2%39.3%
EBITDA i12.12B5.27B
EBITDA Margin i16.9%44.7%
Pre-Tax Income i9.81B4.95B
Pre-Tax Income % of Revenue i13.6%41.9%
Income Tax i1.44B1.23B
Income Tax % of Revenue i2.0%10.4%
Net Income (Profit) i8.36B3.72B
Profit Margin i11.6%31.5%

Balance Sheet & Liquidity Metrics

MetricJUBLPHARMA (2025)CONCORDBIO (2025)
Cash & Equivalents i10.86B9.05M
Total Current Assets i35.77B11.35B
Total Current Assets % of Revenue i49.7%96.2%
Total Current Liabilities i21.65B1.84B
Total Current Liabilities % of Revenue i30.1%15.6%
Long-Term Debt i23.89B6.30M
Long-Term Debt % of Revenue i33.2%0.1%
Total Shareholders Equity i62.39B18.13B
Retained Earnings i53.02B16.91B
Retained Earnings % of Revenue i73.7%143.3%
Property, Plant & Equipment i24.54B667.94M

Cash Flow Statement Comparison

MetricJUBLPHARMA (2025)CONCORDBIO (2025)
Operating Cash Flow i8.86B2.98B
Operating Cash Flow % of Revenue i12.3%25.3%
Capital Expenditures i-11.11B-1.11B
Free Cash Flow i-435.00M1.33B
FCF Margin i-0.6%11.3%
Debt Repayment i-11.00B-58.59M
Common Stock Repurchase i-56.00MN/A

Short Interest & Institutional Ownership Analysis

MetricJUBLPHARMACONCORDBIO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i158.39M104.62M
Float Shares i63.53M26.95M
% Held by Insiders i57.94%74.26%
% Held by Institutions i20.51%13.16%
% Held by Public i21.55%12.58%

Dividend Analysis & Yield Comparison: Jubilant Pharmova Ltd. vs Concord Biotech Ltd.

MetricJUBLPHARMACONCORDBIO
Last 12-Month Dividend i₹10.00₹8.75
Last 12-Month Dividend Yield i0.85%0.44%
3-Year Avg Annual Dividend i₹6.67₹2.92
3-Year Avg Dividend Yield i0.89%0.56%
3-Year Total Dividends i₹20.00₹8.75
Ex-Dividend DateJul 25, 2025Jun 21, 2024